Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.
CSPC Pharmaceutical Group has secured European Union marketing authorisation for its independently developed Amphotericin B Liposomal, Powder for Concentrate for Dispersion for Infusion (HC1507G2). The product is indicated for severe systemic or deep fungal infections and empirical treatment of presumed fungal infections in febrile neutropenic patients who do not respond to broad-spectrum antibiotics.
As a liposomal formulation, the drug is designed to concentrate at infection sites while reducing exposure in healthy tissues, lowering the risks of nephrotoxicity and infusion-related reactions and improving the therapeutic index. This first-ever Chinese liposomal formulation approved in Europe marks a significant milestone in CSPC’s global expansion of high-end formulations, strengthens its anti-infection pipeline, and enhances its competitive position in the international market while broadening treatment options for patients with serious fungal infections.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on high-end drug formulations and complex injectable medicines. The group develops, manufactures and markets treatments across therapeutic areas including anti-infectives, leveraging in-house R&D, large-scale production and quality management capabilities to expand globally.
Average Trading Volume: 102,317,891
Technical Sentiment Signal: Buy
Current Market Cap: HK$101.3B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.